Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Comparison of dynamic treatment regimes via inverse probability weighting.

Hernán MA, Lanoy E, Costagliola D, Robins JM.

Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):237-42. Review.

5.

Demystifying optimal dynamic treatment regimes.

Moodie EE, Richardson TS, Stephens DA.

Biometrics. 2007 Jun;63(2):447-55.

PMID:
17688497
6.

Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias.

Howe CJ, Cole SR, Chmiel JS, Muñoz A.

Am J Epidemiol. 2011 Mar 1;173(5):569-77. doi: 10.1093/aje/kwq385. Epub 2011 Feb 2.

7.

Regression modeling of semicompeting risks data.

Peng L, Fine JP.

Biometrics. 2007 Mar;63(1):96-108.

PMID:
17447934
8.

Estimation for the optimal combination of markers without modeling the censoring distribution.

Chiang CT, Huang SY.

Biometrics. 2009 Mar;65(1):152-8. doi: 10.1111/j.1541-0420.2007.01040.x. Epub 2008 Apr 16.

PMID:
18422791
9.

Estimating lifetime or episode-of-illness costs under censoring.

Basu A, Manning WG.

Health Econ. 2010 Sep;19(9):1010-28. doi: 10.1002/hec.1640. Erratum in: Health Econ. 2011 Jan;20(1):125-6.

PMID:
20665908
10.
11.

Analysis of failure time data with dependent interval censoring.

Finkelstein DM, Goggins WB, Schoenfeld DA.

Biometrics. 2002 Jun;58(2):298-304.

PMID:
12071402
12.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

PMID:
18199042
13.

Constructing inverse probability weights for marginal structural models.

Cole SR, Hernán MA.

Am J Epidemiol. 2008 Sep 15;168(6):656-64. doi: 10.1093/aje/kwn164. Epub 2008 Aug 5.

14.

Estimating the effect of zidovudine on Kaposi's sarcoma from observational data using a rank preserving structural failure-time model.

Joffe MM, Hoover DR, Jacobson LP, Kingsley L, Chmiel JS, Visscher BR, Robins JM.

Stat Med. 1998 May 30;17(10):1073-102. Review.

PMID:
9618771
15.

Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death.

Cole SR, Hudgens MG, Tien PC, Anastos K, Kingsley L, Chmiel JS, Jacobson LP.

Am J Epidemiol. 2012 Mar 1;175(5):381-90. doi: 10.1093/aje/kwr346. Epub 2012 Feb 1. Erratum in: Am J Epidemiol. 2012 Apr 1;175(7):732.

16.

Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death.

Cole SR, Jacobson LP, Tien PC, Kingsley L, Chmiel JS, Anastos K.

Am J Epidemiol. 2010 Jan 1;171(1):113-22. doi: 10.1093/aje/kwp329. Epub 2009 Nov 24.

17.

Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.

Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD; EuroSIDA Study Group.

AIDS. 2008 Oct 18;22(16):2187-98. doi: 10.1097/QAD.0b013e328310e04f.

PMID:
18832882
18.

Worth the weight: using inverse probability weighted Cox models in AIDS research.

Buchanan AL, Hudgens MG, Cole SR, Lau B, Adimora AA; Women's Interagency HIV Study.

AIDS Res Hum Retroviruses. 2014 Dec;30(12):1170-7. doi: 10.1089/AID.2014.0037.

Supplemental Content

Support Center